Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female adults aged ≥40 years, who have signed an Informed Consent Form prior to initiation of any study-related procedure.~2. Patients with moderate to severe stable Chronic Obstructive Pulmonary Disease (COPD) according to the Global Initiative for Obstructive Lung Disease (GOLD) Guidelines 2006.~3. Patients who have smoking history of at least 10 pack years.~4. Patients with a post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) ≥30% and \< 80% of the predicted normal and post-bronchodilator FEV1/Forced Vital Capacity (FVC) \<0.70.~Exclusion Criteria:~1. Pregnant or nursing women, or women of child-bearing potential, regardless of whether or not sexually active if they are not using acceptable methods of contraception.~2. Patients requiring long term oxygen therapy (\> 15 hours a day) on a daily basis for chronic hypoxemia, or who have been hospitalized or visited an emergency department for a COPD exacerbation or as result of their airways disease in the 6 weeks prior to screening.~3. Patients who have had a respiratory tract infection within 6 weeks prior to screening.~4. Patients with concomitant pulmonary disease, pulmonary tuberculosis (unless confirmed by chest x-ray to be no longer active) or clinically significant bronchiectasis.~5. Patients with any history of asthma indicated by (but not limited to) a blood eosinophil count \> 400/mm3.~6. Patients who, in the judgment of the investigator or the responsible Novartis personnel, have a clinically relevant laboratory abnormality or a clinically significant condition.~7. Patients with uncontrolled Type I and Type II diabetes.~8. History of malignancy of any organ system (including lung cancer), treated or untreated, within the past 5 years.~9. Patients who are contraindicated for or who have shown an untoward reaction to inhaled anticholinergic agents.~10. Patients with a history of long QT syndrome or whose QTc interval (Fridericia method) measured at screening is prolonged (\>450 ms for males or \>470 ms for females).~11. Patients with a history of untoward reactions to sympathomimetic amines, inhaled medication or any component thereof, or any of the study drugs or drugs with similar chemical structures.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- indacaterol/glycopyrrolate 300/50 μg (Type: EXPERIMENTAL): One indacaterol/glycopyrrolate 300/50 μg capsule + 1 placebo capsule inhaled once daily via a single dose dry powder inhaler for 7 days.
- indacaterol 600 μg (Type: ACTIVE_COMPARATOR): Two indacaterol 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
- indacaterol 300 μg (Type: ACTIVE_COMPARATOR): One capsule indacaterol 300 μg + one placebo capsule inhaled once daily via a single dose dry powder inhaler for 7 days.
- placebo (Type: PLACEBO_COMPARATOR): Two placebo capsules inhaled once daily via a single dose dry powder inhaler for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).